Viewing Protocol Section

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT05696626
Ignite Creation Date: 2024-05-06 @ 6:31 PM
Last Modification Date: 2024-10-26 @ 2:50 PM
Study NCT ID: NCT05696626
Protocol Section: NCT05696626
Start Identification Module Data
Expand Identification Module Data
Brief Title: Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ERHER2- Breast Cancer with an ESR1 Mutation
Official Title: An Open Label Randomized Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men with Locally Advanced or Metastatic ERHER2- Breast Cancer with an ESR1 Mutation
Acronym: ELAINEIII
Organization: Sermonix Pharmaceuticals Inc
Organization Class: INDUSTRY
Organization Study ID: SMX 22-002
Start Status Module Data
Status Verified Date: 2024-06
Overall Status: RECRUITING
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Sermonix Pharmaceuticals Inc
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Sermonix Pharmaceuticals Inc
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload